Case Detail

Case Summary

Myriad: Breast Cancer Testing in the United States (B)

Case Number: 5-304-504(B), Year Published: 2004

HBS Number: KEL053

Request PreviewBuy

Authors: Daniel Diermeier; Shobita Parthasarathy

Key Concepts

Health Care, Genetic Testing, Patient Advocacy, Non-government organizations, Patenting, Global

Abstract

The case describes Myriad Genetics and its struggle to develop a genetic testing service while facing challenges from competitors and activist organizations. After Myriad’s discovery of the BRCA gene, capable of genetic testing for breast cancer in women, Myriad would need to choose a strategy to provide this service to the public. With several major competitors offering similar services, intense media scrutiny, and a charged activist and political climate, a poor Myriad decision could face major repercussions.

Number of Pages: 15

Extended Case Information

Teaching Areas: Biotechnology, Finance, Management, Marketing, Strategy, Technology

Geographic: United States

Industry: Genetic Testing

Organization Name: Myriad Genetics

Organization Size: Small

Year of Case: 1998